Drug Type Gene therapy |
Synonyms Lenti-TH-AADC-CH1, Parkinson's disease gene therapy, Parkinson's disease gene therapy(Oxford Biomedica Plc) + [4] |
Target |
Mechanism DDC gene transference |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Start Date17 Oct 2018 |
Sponsor / Collaborator |
Start Date01 May 2011 |
Sponsor / Collaborator |
Start Date01 Jan 2008 |
Sponsor / Collaborator |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Parkinson Disease | Phase 2 | GB | 01 Jan 2008 | |
Parkinson Disease | Phase 2 | FR | 01 Jan 2008 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 2 | 4 | (crjxqslhgb) = nbvkvfgtqh nvncprojir (cjxkxwptfy ) View more | Positive | 06 Oct 2020 | |||
Not Applicable | Parkinson Disease tyrosine hydroxylase | aromatic L-amino acid decarboxylase | GTP-cyclohydrolase | - | OXB-102 full-strength dose | nhwjumvwcz(quvvhldtye) = fbefhbinny nicsvlgdqq (gggijiknyq ) View more | Positive | 01 May 2014 | |
OXB-102 1/5th dose | nhwjumvwcz(quvvhldtye) = ukaamxlhul nicsvlgdqq (gggijiknyq ) View more |